Key Developments: Medtronic Inc (MDT.N)

MDT.N on New York Stock Exchange

58.55USD
17 Apr 2014
Price Change (% chg)

$0.06 (+0.10%)
Prev Close
$58.49
Open
$58.56
Day's High
$59.23
Day's Low
$58.47
Volume
2,422,466
Avg. Vol
1,278,178
52-wk High
$62.89
52-wk Low
$45.40

Search Stocks

Latest Key Developments (Source: Significant Developments)

Medtronic Inc's CRT devices now approved to Treat Patients with AV Block and Reduced Heart Function
Thursday, 10 Apr 2014 07:08pm EDT 

Medtronic Inc:Announces U.S. Food and Drug Administration approved an expanded indication for biventricular pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators.Medtronic CRT devices are now approved to treat patients with atrioventricular block and left ventricular systolic dysfunction, reducing heart failure hospitalizations and mortality, and improving cardiac function in these patients.FDA's approval was based on the BLOCK HF clinical trial, which demonstrated significant clinical advantages of BiV pacing compared with traditional right ventricular (RV) pacing in this patient population.  Full Article

Medtronic Inc announces public offering of senior notes
Friday, 21 Feb 2014 08:22am EST 

Medtronic Inc:Says it registered an offering of $250 mln principal amount of its 0.875 pct Senior Notes due 2017, $250 mln principal amount of its floating rate Senior Notes due 2017.Says it has also registered an offering $850 mln principal amount of its 3.625pct Senior Notes due 2024, and $650 million principal amount of its 4.625% Senior Notes due 2044.Says the closing of the offering is expected to occur on Feb. 27.Says it intends to use the net proceeds for working capital and general corporate purposes, which may include repayment of its indebtedness.  Full Article

Medtronic Inc announces global launch of Miniature Cardiac Monitor, Reveal LINQ ICM
Wednesday, 19 Feb 2014 09:01am EST 

Medtronic Inc:Says U.S. Food and Drug Administration (FDA) 510(k) clearance, CE ( ConformitĂ© EuropĂ©enne ) Mark, and the global launch of its Reveal LINQ Insertable Cardiac Monitor (ICM) System.Says the smallest implantable cardiac monitoring device available for patients.Says Reveal LINQ ICM is about one-third the size of a AAA battery, making it more than 80 pct smaller than other ICMs.  Full Article

Medtronic Inc gives FY 2014 EPS guidance in line with analysts' estimates - Conference Call
Tuesday, 18 Feb 2014 08:00am EST 

Medtronic Inc:Expects FY 2014 earnings per share in the range of $3.81 to $3.83.FY 2014 EPS of $3.82 - Thomson Reuters I/B/E/S.  Full Article

Medtronic Inc announces cash dividend
Thursday, 13 Feb 2014 04:15pm EST 

Medtronic Inc:approves a cash dividend of $0.28 per share of the company's common stock.Says the dividend is payable on Apr. 25 to shareholders of record at the close of business on Apr. 4.  Full Article

Medtronic Inc's CoreValve system obtains early FDA approval on clinical performance
Friday, 17 Jan 2014 10:42am EST 

Medtronic Inc:Says the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve System for severe aortic stenosis patients who are too ill or frail to have their aortic valves replaced through traditional open-heart surgery.Says FDA granted approval of the CoreValve device without an independent device advisory panel review after reviewing the clinical outcomes in the Extreme Risk Study of the CoreValve U.S.Says Pivotal Trial, which demonstrated that the CoreValve System is safe and effective with high rates of survival and some of the lowest rates of stroke and valve leakage reported.Says In the U.S. Pivotal Trial, the CoreValve System also achieved exceptional hemodynamics, or blood flow, post-implant with results similar to the gold standard, surgical valves.  Full Article

Mallinckrodt Plc and Medtronic announce Clinical and Commercial Collaboration
Monday, 13 Jan 2014 08:00am EST 

Mallinckrodt Plc:Says it has entered into a multiyear agreement with Medtronic to advance availability in the U.S. of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.Says under the agreement, the two companies will collaborate on the development and testing of Mallinckrodt`s future intrathecal products for use in Medtronic's SynchroMed Programmable Infusion System.Says the companies will also develop joint marketing and sales programs to increase awareness and adoption of these drug delivery therapies.  Full Article

Medtronic Inc announces acquisition of Tyrx, Inc
Monday, 6 Jan 2014 12:00pm EST 

Medtronic Inc:Says that it has acquired TYRX, Inc, a New Jersey-based developer of implantable combination antibiotic drug and implanted medical devices.Says the all cash transaction includes an initial payment of $160 million plus potential earn out and performance based milestone payments.  Full Article

Medtronic Inc announces cash dividend for third quarter of fiscal year 2014
Thursday, 5 Dec 2013 04:15pm EST 

Medtronic Inc:Approves a cash dividend of $0.28 per share of the Company's common stock.Says the dividend is payable on Jan. 24, 2014, to shareholders of record at the close of business on Jan. 3, 2014.  Full Article

Medtronic Inc Reaffirms FY 2014 Guidance-Conference Call
Tuesday, 19 Nov 2013 08:00am EST 

Medtronic Inc announced that it continue to expect constant currency revenue growth of 3% to 4% remains reasonable for the fiscal 2014 and continue to expect fiscal 2014 non-GAAP diluted earnings per share (EPS) in the range of $3.80 to $3.85. The Company reported revenue of $16.590 billion in fiscal 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.83 for fiscal 2014.  Full Article

Edwards shares up on injunction against Medtronic heart valve

- Shares of Edwards Lifesciences Corp jumped 13 percent on Monday after a U.S. court temporarily halted sales of competitor Medtronic Inc's heart valve implant that uses a less-invasive procedure to spare patients from open-heart surgery.

Search Stocks